argenx SE traded at 361.30 this Monday July 4th, decreasing 1.40 or 0.39 percent since the previous trading session. Looking back, over the last four weeks, argenx SE lost 20.39 percent. Over the last 12 months, its price rose by 40.31 percent. Looking ahead, we forecast argenx SE to be priced at 350.44 by the end of this quarter and at 316.09 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
AstraZeneca 10,808.00 54.00 0.50% 24.54%
Genmab 2,353.00 -8.00 -0.34% -9.19%
Galapagos 53.06 -1.04 -1.92% -8.30%
GRIFOLS 17.84 -0.80 -4.29% -19.44%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Hikma Pharmaceutical 1,654.00 32.50 2.00% -34.78%
UCB 82.64 0.04 0.05% -7.00%

Indexes Price Day Year
BE20 3694 -14.35 -0.39% -11.50%

argenx SE
argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.